Related by context. All words. (Click for frequent words.) 84 Phase Ib 81 Phase 2a 80 Phase 2a trial 79 Phase 2b study 79 Phase Ib clinical 78 Phase IIa 78 Phase 2b trial 77 dose escalation trial 77 Phase 1a 77 Phase IIb 76 Phase 2a clinical 76 Phase III 76 Phase 1b clinical 76 phase 2a 76 Phase 2b 76 phase IIb 76 phase IIa clinical 75 Phase Ib II 75 pivotal Phase III 75 Phase 1b trial 75 Phase II 75 Phase 2b clinical 75 phase Ib 75 Phase Ib study 75 dose escalation Phase 74 placebo controlled Phase 74 Phase IIa clinical 74 Phase IIb clinical 74 dose escalation study 74 Phase IIa trial 74 phase IIa 74 randomized Phase 73 multicenter Phase 73 Phase III clinical 73 dose escalation 72 phase IIb clinical 72 multiple ascending dose 72 Phase IIb trial 72 ongoing Phase 1b 72 pivotal Phase 72 Phase Ia 72 HGS ETR1 71 Phase IIIb clinical 71 BRIM2 70 INCB# [001] 70 Phase 70 GALNS 70 Phase 1a clinical 70 Phase IIa trials 70 pharmacokinetic PK 70 phase IIb study 70 Phase IIb trials 70 dose cohorts 70 CR# vcMMAE 70 confirmatory Phase III 69 randomized controlled Phase 69 IIa trial 69 alvespimycin 69 dose escalation clinical 69 registrational 69 axitinib 69 Phase #b/#a 69 single ascending dose 69 Phase #/#a 69 elotuzumab 68 Phase III pivotal 68 dose cohort 68 blinded randomized placebo controlled 68 ILLUMINATE 68 registrational trial 68 multicenter Phase II 68 placebo controlled Phase III 68 viral kinetic 68 oral ridaforolimus 68 ascending dose 68 deforolimus 68 forodesine 68 glufosfamide 68 SUCCEED trial 68 GLP toxicology studies 67 lintuzumab 67 Phase #b/#a trial 67 Phase Ib clinical trials 67 RDEA# 67 randomized Phase III 67 pertuzumab 67 initiate Phase 67 APEX PD 67 dirucotide 67 relapsed refractory multiple myeloma 67 phase IIb trial 67 Phase IIB 67 R#/MEM # 67 pharmacodynamic PD 67 pharmacokinetics PK 67 HGS# 67 placebo controlled clinical 67 Phase 2b randomized 67 Phase IIIb 67 Initiate Phase 67 PXD# 67 BRIM3 67 LUX Lung 67 dosing cohort 67 TMC# C# 67 HGS ETR2 67 ganetespib 67 ADVANCE PD 67 velafermin 67 Phase III clinical trials 67 MEND CABG 66 randomized Phase 2b 66 XL# [003] 66 pharmacokinetic PK study 66 huC# DM4 66 ofatumumab 66 placebo controlled 66 Pivotal Phase 66 evaluating tivozanib 66 IMA# 66 HuMax EGFr 66 treatment naive genotype 66 PRECiSE 66 multicenter randomized Phase 66 ascending doses 66 Phase IIb clinical trials 66 PEG Interferon lambda 66 PRX # 66 Phase #/#a trial 66 tolerability 66 Phase 2b clinical trials 66 Traficet EN 66 Amrubicin 66 TMC# [002] 66 docetaxel Taxotere R 66 MEND CABG II 66 Cloretazine R VNP#M 66 HER2 positive metastatic breast 65 Initiated Phase 65 IDX# 65 treatment naïve genotype 65 denufosol 65 ISIS # 65 JAK inhibitor 65 Alocrest 65 NO# [002] 65 Randomized Phase 65 Dacogen injection 65 label dose escalation 65 elacytarabine 65 Phase 2a clinical trials 65 CRLX# 65 tanespimycin 65 randomized Phase IIb 65 tolerated dose MTD 65 trodusquemine 65 AEGR 65 Phase 2b Clinical Trial 65 OncoVEX GM CSF 65 IMC A# 65 Phase III Pivotal 65 RG# [001] 65 MLN# 65 Phase #b/#a clinical 65 BCX# 65 Phase III randomized 65 APPRAISE 65 sunitinib malate 65 obatoclax 65 metastatic hormone refractory 65 confirmatory Phase 3 65 IMC #B 65 initiate Phase IIb 65 HCV SPRINT 65 phase Ib clinical 65 PSMA ADC 65 ENDEAVOR IV 65 LEVADEX 65 Phase 1b dose escalation 65 antibody MAb 65 PSN# [002] 65 AIR CF1 64 PEG PAL 64 IMGN# 64 initiate Phase 1b 64 Exherin TM 64 neratinib 64 oral prodrug 64 FOLOTYN ® 64 Cloretazine ® 64 Aplidin 64 multicenter randomized double 64 Phase 1b clinical trials 64 perifosine 64 celgosivir 64 enzastaurin 64 SCH # 64 sapacitabine 64 GetGoal Phase III 64 ELACYT 64 Aflibercept 64 nab paclitaxel 64 PRT# 64 Archexin 64 ARRY 64 HCD# [002] 64 CIMZIA TM 64 Azedra 64 dosing cohorts 64 multicenter randomized placebo controlled 64 rNAPc2 64 Phase IIb Trial 64 CoFactor 64 unblinded 64 tesmilifene 64 randomized multicenter 64 Panzem R NCD 64 rALLy clinical trial 64 GRN#L 64 AeroLEF TM 64 PS# [001] 64 compound INCB# 64 LibiGel Phase III 64 Phase Ib IIa 64 pomalidomide 64 OXi# 64 Plicera 64 OPT CHF 64 dose dose escalation 64 PEG SN# 64 SAR# [004] 64 EVEREST II 63 huN# DM1 63 assessing T DM1 63 Zenvia Phase III 63 multicenter phase 63 clinical trial 63 Bezielle 63 teriflunomide 63 pharmacokinetic 63 carfilzomib 63 Amigal 63 vidofludimus 63 INCB# [002] 63 NP2 Enkephalin 63 AIR CF2 63 double blinded placebo 63 PDE4 inhibitor 63 pharmacodynamic effects 63 TACI Ig 63 XmAb# 63 selective androgen receptor modulator 63 II Clinical Trial 63 aflibercept 63 VEGF Trap 63 ATL# [001] 63 CCX# 63 initiate Phase Ib 63 NVA# 63 Phase III Clinical Trial 63 prospective multicenter 63 REG2 63 velafermin belinostat 63 Sapacitabine 63 AP# [003] 63 Phase III ALLEGRO 63 oral deforolimus 63 IIa clinical 63 MGCD# [001] 63 Phase III randomized controlled 63 fosbretabulin 63 AEG# 63 AQ4N 63 Ozarelix 63 maximally tolerated dose 63 safety tolerability pharmacokinetics 63 preclinical efficacy 63 ASA# 63 GOUT 63 safety tolerability 63 Phase III placebo controlled 63 Sym# 63 otelixizumab 63 relapsed multiple myeloma 63 IMPACT IMmunotherapy 63 CYT# 63 Annamycin 63 ocrelizumab 63 Carfilzomib 63 NGX# 63 HspE7 63 ABSORB trial 63 opioid induced bowel dysfunction 63 Phase III confirmatory 63 PRE SURGE 63 sorafenib Nexavar ® 63 HuMax CD4 63 lomitapide 63 MEK inhibitor RDEA# 63 Pivotal Phase III 63 XL# XL# XL# 63 AEZS 63 Phase IIa clinical trials 63 masked placebo controlled 63 randomized placebo controlled 63 oral FTY# 62 Phase III trials 62 IIa clinical trial 62 eniluracil 62 CA4P 62 eltrombopag 62 dacetuzumab 62 elagolix 62 Imprime PGG 62 ACTEMRA TM 62 Chemophase 62 Quinamed 62 RSD# oral 62 Omacetaxine 62 laquinimod 62 mapatumumab 62 pharmacodynamic 62 TG# [001] 62 nucleotide analog 62 OHR/AVR# 62 BCIRG 62 generation PNP inhibitor 62 lesinurad 62 romidepsin 62 Fx #A 62 rindopepimut 62 eculizumab 62 investigational humanized monoclonal antibody 62 randomized discontinuation trial 62 phase IIIb 62 imetelstat 62 Alzhemed TM 62 GAMMAGARD 62 European Sepsis Trial 62 COU AA 62 initiated Phase Ib 62 multicenter Phase III 62 evaluating RDEA# 62 PF # [001] 62 afatinib 62 Prostate AdenoCarcinoma Treatment 62 KRN# 62 PD LID 62 crizotinib PF # 62 tgAAC# 62 ZYBRESTAT 62 preclinical 62 cannabinor 62 relapsed MM 62 voreloxin 62 Antiviral Activity 62 Pivotal Trial 62 mertansine 62 HDAC Inhibitor 62 QLT# 62 AZILECT R 62 ozarelix 62 ALN VSP Phase 62 Phenoptin 62 Tesetaxel 62 MERLIN TIMI 62 torezolid phosphate 62 Dapagliflozin 62 pharmacokinetic studies 62 Phase IIb Clinical Trial 62 ALN TTR 62 histone deacetylase HDAC inhibitor 62 valopicitabine 62 ZACTIMA 62 confirmatory clinical 62 DASISION 62 IND enabling 62 Phase 2b Trial 62 teduglutide 62 PRTX 62 virus HCV protease inhibitor 62 Phase 2b monotherapy 62 brivaracetam 62 Tarceva TM 62 initiate Phase 2b 62 blind randomized placebo 62 Reolysin 62 multicentre randomized 62 evaluable patients 62 refractory CLL 62 Triolex 62 unblinding 62 MDV# 62 budesonide foam 62 BAY #-# 62 Zerenex 62 ALKS 62 ulimorelin 62 Aurexis 62 Blinatumomab 62 HCV RESPOND 2 62 viral kinetics 62 Capesaris 62 resminostat 62 blinatumomab 62 Perifosine 62 ruxolitinib 62 Azixa 62 LymphoStat B TM 61 AVADO 61 EOquin TM 61 Pivotal Study 61 Phase IIb III 61 Laquinimod 61 Vicinium TM 61 PROSTVAC TM 61 Bicifadine 61 RGB # 61 preclinical studies 61 T DM1 61 custirsen 61 cancer neuroendocrine tumor 61 IMPACT DCM 61 EOquin 61 administered subcutaneously 61 IIa trials 61 Cethromycin 61 Pegasys plus Copegus 61 pharmacokinetic profile 61 telaprevir dosing 61 subcutaneous formulation 61 pharmacodynamics 61 pivotal bioequivalence 61 davunetide intranasal AL 61 adecatumumab 61 Ostarine 61 IIb clinical trial 61 ENDEAVOR III 61 multicenter placebo controlled 61 dacetuzumab SGN 61 IND submission 61 ThermoDox R 61 RE SURGE 61 CRMD# 61 bardoxolone 61 ORMD 61 Cloretazine 61 Pivotal Trials 61 Combination REOLYSIN R 61 Xanafide 61 Cotara 61 orally bioavailable 61 TAXUS ATLAS 61 picoplatin 61 Phase III Trial 61 COMFORT II 61 BLA submission 61 leading oral taxane 61 label multicenter 61 Exelixis XL# 61 APTIVUS 61 clinical pharmacology studies 61 gemcitabine Gemzar ® 61 SPIRIT FIRST 61 ANCHOR trial 61 Maximum Tolerated Dose 61 dose limiting toxicities 61 Fibrillex TM 61 OMP #M# 61 seliciclib CYC# 61 mCRC 61 Ocrelizumab 61 multicenter randomized controlled 61 dependent kinase inhibitor 61 talactoferrin 61 palifosfamide 61 CEQ# 61 EchoCRT 61 recurrent glioma 61 placebo controlled dose escalation 61 PROMACTA 61 ularitide 61 LymphoStat B 61 trastuzumab emtansine T DM1 61 SABCS 61 Androxal TM 61 AZX# Phase 61 Phase Ib Clinical Trial 61 trastuzumab DM1 T DM1 61 multicenter randomized 61 Tanespimycin 61 Marqibo 61 Phase 2b kidney transplant 61 AVOREN 61 Pharmacokinetics PK 61 pharmacodynamic profile 61 blinded placebo controlled 61 LBH# 61 TASKi2 61 MOZOBIL 61 farletuzumab 61 bicifadine 61 CRx 61 ARDIS 61 riociguat 61 daclizumab 61 dose escalation phase 61 BR.# 61 metaglidasen 61 mipomersen 61 CCR5 mAb 61 Phase III Clinical Trials 61 VNP#M 61 Hsp# Inhibitor 61 evaluating mipomersen 61 COSIRA trial 61 MBP# [001] 61 double blinded randomized 61 tivozanib 61 nitazoxanide 61 ARIKACE 61 stated Michelle Berrey 61 IRX 2 61 Daclizumab 61 tezampanel 61 Glufosfamide 61 Dose escalation 61 PLK1 SNALP 61 vascular disrupting agent 61 nonclinical studies 61 OncoGel 61 Actilon 61 Multiple Ascending Dose 61 alvimopan 61 Pralatrexate 61 L MTP PE 61 double blind placebo 61 HuMax CD# 61 randomized double 61 multicenter 61 Allovectin 7 R 61 Vitaxin 61 EDEMA3 61 MAGE A3 ASCI 61 Proxinium TM 61 investigational compound 61 ORACLE MS 61 monotherapy 61 HCV protease inhibitor 61 MEK inhibitor 61 dexpramipexole 60 entinostat 60 PRX# 60 placebo controlled randomized 60 ZFP Therapeutic 60 varespladib 60 anticancer compound 60 Augment Injectable 60 Locteron 60 L BLP# 60 PDX pralatrexate 60 safety tolerability pharmacokinetic 60 pradefovir 60 lintuzumab SGN 60 bapineuzumab AAB 60 lorvotuzumab mertansine 60 dyskinesia PD LID 60 controlled multicenter 60 rilonacept 60 ALN VSP 60 XL# XL# XL# XL# 60 ELND# 60 AKT inhibitor 60 ToGA 60 REVIVE Diabetes 60 multicentre 60 FOLFOX6 chemotherapy regimen 60 TG MV 60 label multicenter Phase 60 Allovectin 7 ® 60 randomized #:# 60 Genz # 60 telomerase inhibitor drug 60 NOX E# 60 Phase III psoriasis 60 Zenvia ™ 60 Dose Escalation 60 TELCYTA 60 alemtuzumab Campath 60 Phase IIIb study 60 randomized controlled 60 YONDELIS 60 Allovectin 7 60 DermaVir Patch 60 PANVAC VF 60 FOLOTYN 60 rALLy trial 60 secondary efficacy endpoints 60 bosutinib 60 EndoTAG TM -1 60 favorable pharmacokinetic profile 60 belinostat 60 null responder HCV 60 Randomized Phase II 60 MAA submission 60 midstage clinical 60 PHX# 60 methylnaltrexone 60 REOLYSIN ® 60 aclidinium 60 MAXY alpha 60 cell lymphoma CTCL 60 subcutaneously administered 60 interferon gamma 1b 60 oral rivaroxaban 60 DURATION 60 volociximab 60 tezampanel NGX# 60 randomized controlled multicenter 60 galiximab 60 rALLy 60 Phase 2b Study 60 multicenter clinical 60 investigational pan BCR 60 fostamatinib 60 Tyrima 60 tremelimumab 60 Mipomersen 60 Urocortin 2 60 XL# SAR# 60 NXL# 60 randomized multicenter Phase III 60 ENDEAVOR II 60 FTY# fingolimod 60 dirucotide MBP# 60 ROCKET AF 60 mg/m2 dose 60 Board DSMB 60 EFAPROXYN 60 receptor tyrosine kinase inhibitor 60 lead Aganocide compound 60 vicriviroc 60 polymerase inhibitor 60 trial evaluating PRX# 60 pharmacokinetics 60 pharmacodynamics PD 60 APOPTONE 60 CBLC# 60 active comparator 60 omacetaxine mepesuccinate 60 antitumor activity 60 TOLAMBA 60 advanced carcinoid 60 Vicriviroc 60 humanized monoclonal antibody 60 heavily pretreated 60 metastatic castration resistant 60 LymphoStat B belimumab 60 nonrandomized 60 lixisenatide 60 Metastatic Melanoma 60 Restanza 60 CIMZIA ™ 60 imetelstat GRN#L 60 initiate Phase IIa 60 Ophena TM 60 SNT MC# 60 Clinical Trial Results 60 desvenlafaxine succinate 60 confirmatory Phase 60 CTCE 60 pralatrexate 60 DSMB 60 seliciclib 60 CYT# potent vascular disrupting 60 DDP# 60 Aplidin R 60 CLL8 60 ADAGIO study 60 GSK# [001] 60 CAMMS# 60 ProSavin 60 tramiprosate Alzhemed TM 60 AMD# [003] 60 Urocidin 60 recurrent glioblastoma multiforme 60 investigational oral 60 Phase IIa proof 60 Meets Primary Endpoint 60 ALN TTR# 60 prospectively defined 60 TBC# 60 bendamustine 60 CB2 selective receptor agonist 60 DB# [003] 60 cilengitide 60 lumiliximab 60 ITMN 60 novel histone deacetylase 60 PEGylated interferon beta 1a 60 PMX # 60 abiraterone acetate 60 ritonavir boosted 60 Alpharadin 60 BRAF inhibitor 60 Troxatyl 60 Viramidine 60 Virulizin ® 60 thorough QT 60 Panzem R 59 plus Copegus R 59 ZK EPO 59 rFIXFc 59 INT# [002] 59 maribavir 59 GRN# 59 Debio 59 subcutaneous PRO 59 Enzastaurin 59 Targretin 59 efficacy endpoint 59 evaluating T DM1 59 bavituximab 59 docetaxel chemotherapy 59 Aptivus ® 59 safinamide 59 CONSERV 59 talabostat 59 Elagolix 59 CLARITY study 59 Aryplase 59 ACTEMRA 59 AVN# [001] 59 metastatic renal cell 59 CCR9 antagonist 59 Corlux 59 telaprevir VX 59 SPIRIT IV 59 HuLuc# 59 TOCOSOL Paclitaxel 59 Bortezomib 59 pegylated interferon alpha 59 ORENCIA ® 59 Zenvia TM 59 prucalopride 59 Phase 2a Clinical Trial 59 tolerability profile 59 Relovair 59 ataluren 59 CLORETAZINE TM VNP#M 59 PFO migraine 59 metastatic castrate resistant 59 PEG IFN 59 Pimavanserin 59 visilizumab 59 microplasmin 59 ONCONASE R 59 orally administered inhibitor 59 mGluR5 negative 59 Trofex 59 urocortin 2 59 Telatinib 59 Initiates Phase 59 eprotirome 59 relapsing multiple sclerosis 59 DSMB recommended 59 edoxaban 59 trastuzumab Herceptin R 59 VP# [004] 59 PREOS R 59 CCX# B 59 preclinical pharmacokinetic 59 LUMINATE 59 PNP inhibitor 59 TKB# 59 Diamyd ® 59 FORTIS M trial 59 cediranib 59 RG# ITMN 59 Guanilib 59 Phase III Trials 59 odanacatib 59 depsipeptide 59 JAK1 59 R# #mg BID 59 comparing alemtuzumab 59 angiogenesis inhibitor 59 Atu# 59 multicenter prospective 59 MNTX 59 relapsed refractory AML 59 reslizumab 59 dextromethorphan quinidine 59 CTAP# Capsules 59 Phase lll 59 AIMM trial 59 Phase III metastatic melanoma 59 Bayer HealthCare Onyx Pharmaceuticals 59 non nucleoside inhibitor 59 STRIDE PD 59 satraplatin Phase 59 Aclidinium 59 apremilast 59 Relapsed Multiple Myeloma 59 zanolimumab 59 cariprazine 59 adecatumumab MT# 59 TYKERB 59 #I TM# 59 randomized clinical 59 mCRC patients 59 ONCONASE 59 MT# MEDI 59 Elotuzumab 59 liposomal formulation 59 ABSORB clinical 59 plus dexamethasone 59 Apoptone 59 aclidinium bromide 59 neurogenic orthostatic hypotension 59 atacicept 59 generation NNRTI 59 Symadex 59 metastatic sarcomas 59 zalutumumab 59 Kahalalide F 59 RSD# 59 ISTODAX ® 59 Factor VIIa 59 Ceflatonin R 59 Study Evaluating 59 MAP# 59 Diabetic Macular Edema 59 phase IIb III 59 novel VDA molecule 59 recurrent glioblastoma 59 ixabepilone 59 FAME Study 59 acyclovir Lauriad R 59 diabetic neuropathic pain 59 immunotherapeutic agent 59 KRAS mutations occur 59 Genasense oblimersen sodium Injection 59 Altastaph 59 oral sapacitabine 59 solithromycin 59 μg dose 59 multicenter dose escalation 59 oral picoplatin 59 telaprevir dosed 59 radezolid 59 cangrelor 59 Shigamabs ® 59 Serdaxin 59 Radezolid 59 daily Infergen 59 refractory AML 59 NDA submission 59 BOLDER II 59 Cimzia ® certolizumab pegol 59 temsirolimus 59 Virulizin R 59 trastuzumab DM1 59 albiglutide 59 BLA filing 59 initiated Phase 1b 59 Acute Ischemic Stroke 59 PARTNER Trial 59 OncoVEX 59 PRIMO CABG2 59 label multicenter randomized 59 prospective multicenter randomized 59 Trial Evaluating 59 ENMD 59 Golimumab 59 TRO# 59 RE LY 59 CALGB # [002] 59 vandetanib 59 Sorafenib HCC Assessment 59 IL# PE#QQR 59 HQK 59 tolerability pharmacokinetics 59 Defibrotide 59 ThermoDox ® 59 INGN 59 decitabine 59 CHAMPION PCI 59 antiviral activity 59 Completes Patient Enrollment 59 midstage trials 59 blind placebo controlled 59 unique alkylating agent 59 oral formulation 59 OvaRex ® MAb 59 clinical trials Multikine 59 pazopanib 59 RAV# 59 prospective randomized placebo 59 Achieves Primary Endpoint 59 TRANSFORMS 59 QNEXA 59 EVIZON 59 ZYBRESTAT fosbretabulin 59 Cethrin 59 ACAPODENE 59 Tovaxin 59 Curaxin CBLC# 59 Protease Inhibitor 59 JZP 59 OncoVex 58 AACR NCI EORTC 58 investigational monoclonal antibody 58 ceftaroline 58 motesanib 58 amrubicin 58 anti leukemic 58 TLK# 58 recurrent malignant glioma 58 KNS # 58 VICTOR E1 58 pharmacokinetic pharmacodynamic 58 ALN RSV# 58 EndoTAG 58 palifosfamide Zymafos TM 58 Synavive 58 Proellex TM 58 inhibitor RG# 58 relapsing remitting multiple sclerosis 58 ASONEP 58 CD NP 58 sunitinib 58 lucinactant 58 octreotide implant 58 XL# XL# 58 Voreloxin 58 Clolar ® 58 ANYARA 58 darusentan 58 Initiates Phase II 58 GLPG# 58 generation purine nucleoside 58 IIa clinical trials 58 paclitaxel poliglumex 58 tesetaxel 58 baminercept 58 Dextofisopam 58 TRIOLEX 58 phase III ACCLAIM 58 NU# [001] 58 hour bronchodilation 58 Phase 2a proof 58 regorafenib 58 azilsartan medoxomil 58 albinterferon alfa 2b 58 ritonavir boosted danoprevir 58 ostarine 58 PROVENGE ® 58 carboplatin paclitaxel 58 generation Hsp# inhibitor 58 aplindore 58 FOLFOX6 58 low dose cytarabine 58 nucleoside analog 58 PI3K/Akt pathway inhibitor 58 #th Annual Interscience 58 Zybrestat 58 standard chemotherapy regimen 58 ANA# 58 Hsp# inhibitor 58 ZD# [001] 58 Phase III HEAT 58 CUSTOM III 58 KSP inhibitor 58 Parkinson disease levodopa induced 58 dose pharmacokinetic 58 Vascular Disrupting Agent 58 Personalized Immunotherapy 58 EGS# 58 labial herpes 58 SYMMETRY trial 58 Alfimeprase 58 RELOVAIR ™ 58 Brentuximab Vedotin SGN 58 randomized controlled clinical 58 PRIMO CABG 58 avanafil 58 drug pipeline TAFA# 58 BIBW 58 dose regimens 58 CTA# Injection 58 APTIVUS r 58 randomized 58 bavituximab monotherapy trial 58 Phase III VISTA 58 Phase 2a Study 58 CD# CEA 58 Prospective Randomized 58 LE DT